CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and Dexamethasone（CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.
Extramedullary Plasmacytoma
DRUG: CDD|DRUG: CDD Plus Bortezomib
Number of patients with overall hematologic response, Complete response, very good partial response and partial response, Assessed every 2 cycles (median length of the endpoint assessment period is projected to be approximately 24 months)
Number of patients with EMP response, response rate, Assessed every 2 cyeles period is projected to be approximately 24 months|Overall survival, The median overall survival, Monthly up to 3 years|Time from diagnosis ofEMP to the date of death, Monthly up to 3 years|Progression free survival, Monthly up to 2 years|Time from date of diagnosis of EMP to the date of first documentation of disease, Monthly up to 2 years|Number of adverse events, Adverse events, serious adverse events, assessment of clinical laboratory values from the date of signing of the informed consent form through 30 days after the last dose of study drug., Monthly up to 3 years
The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and Dexamethasone（CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.